{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:23:58Z","timestamp":1791563038413,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00277-024-05683-2","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T17:02:11Z","timestamp":1709744531000},"page":"3839-3853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"given":"Hongpeng","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"5683_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD et al (2020) Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21:1317\u20131330. https:\/\/doi.org\/10.1016\/S1470-2045(20)30452-6","journal-title":"Lancet Oncol"},{"key":"5683_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/cells11040606","volume":"11","author":"S Mor\u00e8","year":"2022","unstructured":"Mor\u00e8 S, Corvatta L, Manieri VM et al (2022) Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go? Cells 11:606. https:\/\/doi.org\/10.3390\/cells11040606","journal-title":"Cells"},{"key":"5683_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C et al (2017) Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. New England Journal of Medicine 376:1311\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"New England Journal of Medicine"},{"key":"5683_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed R, Bazarbachi AH, Malard F et al (2019) Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J 9:44. https:\/\/doi.org\/10.1038\/s41408-019-0205-9","journal-title":"Blood Cancer J"},{"key":"5683_CR5","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1002\/cncr.32060","volume":"125","author":"R Mina","year":"2019","unstructured":"Mina R, Lonial S (2019) Is there still a role for stem cell transplantation in multiple myeloma? Cancer 125:2534\u20132543. https:\/\/doi.org\/10.1002\/cncr.32060","journal-title":"Cancer"},{"key":"5683_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","volume":"12","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi AH, Al Hamed R, Malard F et al (2022) Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J 12:47. https:\/\/doi.org\/10.1038\/s41408-022-00645-1","journal-title":"Blood Cancer J"},{"key":"5683_CR7","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M et al (2020) Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7:e456\u2013e468. https:\/\/doi.org\/10.1016\/S2352-3026(20)30099-5","journal-title":"Lancet Haematol"},{"key":"5683_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2012.323","volume":"27","author":"S Li","year":"2013","unstructured":"Li S, Fu J, Ma H et al (2013) Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia 27:1407\u20131411. https:\/\/doi.org\/10.1038\/leu.2012.323","journal-title":"Leukemia"},{"key":"5683_CR9","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T et al (2021) Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22:1582\u20131596. https:\/\/doi.org\/10.1016\/S1470-2045(21)00466-6","journal-title":"Lancet Oncol"},{"key":"5683_CR10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2023) Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 41:1590\u20131599. https:\/\/doi.org\/10.1200\/JCO.22.00940","journal-title":"J Clin Oncol"},{"key":"5683_CR11","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1097\/HS9.0000000000000528","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E et al (2021) Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere 5:e528. https:\/\/doi.org\/10.1097\/HS9.0000000000000528","journal-title":"Hemasphere"},{"key":"5683_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"M-V Mateos","year":"2013","unstructured":"Mateos M-V, Hern\u00e1ndez M-T, Giraldo P et al (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369:438\u2013447. https:\/\/doi.org\/10.1056\/NEJMoa1300439","journal-title":"N Engl J Med"},{"key":"5683_CR13","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar S, Dispenzieri A, Lacy MQ et al (2007) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21:2035\u20132042. https:\/\/doi.org\/10.1038\/sj.leu.2404801","journal-title":"Leukemia"},{"key":"5683_CR14","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","volume":"22","author":"H Paripati","year":"2008","unstructured":"Paripati H, Stewart AK, Cabou S et al (2008) Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 22:1282\u20131284. https:\/\/doi.org\/10.1038\/sj.leu.2405100","journal-title":"Leukemia"},{"key":"5683_CR15","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00520-013-1808-5","volume":"21","author":"D Bhutani","year":"2013","unstructured":"Bhutani D, Zonder J, Valent J et al (2013) Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. Support Care Cancer 21:2437\u20132442. https:\/\/doi.org\/10.1007\/s00520-013-1808-5","journal-title":"Support Care Cancer"},{"key":"5683_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/10428194.2016.1239261","volume":"58","author":"A Ogunniyi","year":"2017","unstructured":"Ogunniyi A, Rodriguez M, Devlin S et al (2017) Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leuk Lymphoma 58:1123\u20131129. https:\/\/doi.org\/10.1080\/10428194.2016.1239261","journal-title":"Leuk Lymphoma"},{"key":"5683_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41409-020-01033-8","volume":"56","author":"V Laurent","year":"2021","unstructured":"Laurent V, Fronteau C, Antier C et al (2021) Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant 56:395\u2013399. https:\/\/doi.org\/10.1038\/s41409-020-01033-8","journal-title":"Bone Marrow Transplant"},{"key":"5683_CR18","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG et al (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119:4375\u20134382. https:\/\/doi.org\/10.1182\/blood-2011-11-395749","journal-title":"Blood"},{"key":"5683_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","volume":"15","author":"U Popat","year":"2009","unstructured":"Popat U, Saliba R, Thandi R et al (2009) Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15:718\u2013723. https:\/\/doi.org\/10.1016\/j.bbmt.2009.02.011","journal-title":"Biol Blood Marrow Transplant"},{"key":"5683_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/bmt.2012.281","volume":"48","author":"M Pozotrigo","year":"2013","unstructured":"Pozotrigo M, Adel N, Landau H et al (2013) Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant 48:1033\u20131039. https:\/\/doi.org\/10.1038\/bmt.2012.281","journal-title":"Bone Marrow Transplant"},{"key":"5683_CR21","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/bmt.2012.60","volume":"47","author":"LJ Costa","year":"2012","unstructured":"Costa LJ, Abbas J, Hogan KR et al (2012) Growth factor plus preemptive ('just-in-time\u2019) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 47:1403\u20131408. https:\/\/doi.org\/10.1038\/bmt.2012.60","journal-title":"Bone Marrow Transplant"},{"key":"5683_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbmt.2014.09.020","volume":"21","author":"P Samaras","year":"2015","unstructured":"Samaras P, Pfrommer S, Seifert B et al (2015) Efficacy of Vinorelbine Plus Granulocyte Colony\u2013Stimulation Factor for CD34+ Hematopoietic Progenitor Cell Mobilization in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 21:74\u201380. https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"5683_CR23","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1080\/10428194.2019.1573367","volume":"60","author":"T Dosani","year":"2019","unstructured":"Dosani T, Covut F, Pinto R et al (2019) Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leuk Lymphoma 60:2199\u20132206. https:\/\/doi.org\/10.1080\/10428194.2019.1573367","journal-title":"Leuk Lymphoma"},{"key":"5683_CR24","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1111\/trf.14220","volume":"57","author":"A Partanen","year":"2017","unstructured":"Partanen A, Valtola J, Silvennoinen R et al (2017) Impact of lenalidomide-based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study. Transfusion 57:2366\u20132372. https:\/\/doi.org\/10.1111\/trf.14220","journal-title":"Transfusion"},{"key":"5683_CR25","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/cam4.3762","volume":"10","author":"L Xu","year":"2021","unstructured":"Xu L, Liu J, Huang B et al (2021) Comparison of efficacy, safety, patients\u2019 quality of life, and doctors\u2019 occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma. Cancer Med 10:1656\u20131667. https:\/\/doi.org\/10.1002\/cam4.3762","journal-title":"Cancer Med"},{"key":"5683_CR26","doi-asserted-by":"publisher","first-page":"661.e1","DOI":"10.1016\/j.jtct.2021.04.010","volume":"27","author":"AJ Cowan","year":"2021","unstructured":"Cowan AJ, Stevenson PA, Green DJ et al (2021) Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis. Transplant Cell Ther 27:661.e1\u2013661.e6. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.010","journal-title":"Transplant Cell Ther"},{"key":"5683_CR27","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136:936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"5683_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394:29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1","journal-title":"Lancet"},{"key":"5683_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-142115","volume":"136","author":"S Manjappa","year":"2020","unstructured":"Manjappa S, Fox R, Reese J et al (2020) Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood 136:35\u201337. https:\/\/doi.org\/10.1182\/blood-2020-142115","journal-title":"Blood"},{"key":"5683_CR30","doi-asserted-by":"publisher","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","volume":"7","author":"J Ghose","year":"2018","unstructured":"Ghose J, Viola D, Terrazas C et al (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948. https:\/\/doi.org\/10.1080\/2162402X.2018.1486948","journal-title":"Oncoimmunology"},{"key":"5683_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/nyas.12485","volume":"1335","author":"V Quarona","year":"2015","unstructured":"Quarona V, Ferri V, Chillemi A et al (2015) Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci 1335:10\u201322. https:\/\/doi.org\/10.1111\/nyas.12485","journal-title":"Ann N Y Acad Sci"},{"key":"5683_CR32","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1002\/ajh.25654","volume":"95","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Sidiqi MH, Gertz MA et al (2020) Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. Am J Hematol 95:E8\u2013E10. https:\/\/doi.org\/10.1002\/ajh.25654","journal-title":"Am J Hematol"},{"key":"5683_CR33","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","volume":"106","author":"C Hulin","year":"2021","unstructured":"Hulin C, Offner F, Moreau P et al (2021) Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica 106:2257\u20132260. https:\/\/doi.org\/10.3324\/haematol.2020.261842","journal-title":"Haematologica"},{"key":"5683_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-140811","volume":"136","author":"D Luan","year":"2020","unstructured":"Luan D, Christos PJ, Ancharski M et al (2020) Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use. Blood 136:15\u201316. https:\/\/doi.org\/10.1182\/blood-2020-140811","journal-title":"Blood"},{"key":"5683_CR35","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.rec.2021.07.010","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed) 74:790\u2013799. https:\/\/doi.org\/10.1016\/j.rec.2021.07.010","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"5683_CR36","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/bloodadvances.2020003642","volume":"5","author":"PM Voorhees","year":"2021","unstructured":"Voorhees PM, Rodriguez C, Reeves B et al (2021) Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv 5:1092\u20131096. https:\/\/doi.org\/10.1182\/bloodadvances.2020003642","journal-title":"Blood Adv"},{"key":"5683_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"5683_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13","journal-title":"BMC Med Res Methodol"},{"key":"5683_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/bimj.201900036","volume":"62","author":"S McGrath","year":"2020","unstructured":"McGrath S, Sohn H, Steele R, Benedetti A (2020) Meta-analysis of the difference of medians. Biom J 62:69\u201398. https:\/\/doi.org\/10.1002\/bimj.201900036","journal-title":"Biom J"},{"key":"5683_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"C Lo","year":"2014","unstructured":"Lo C, Mertz D, Loeb M (2014) Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol 14:1\u20135. https:\/\/doi.org\/10.1186\/1471-2288-14-45","journal-title":"BMC Med Res Methodol"},{"key":"5683_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"5683_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","volume":"28","author":"RK Hopman","year":"2014","unstructured":"Hopman RK, DiPersio JF (2014) Advances in stem cell mobilization. Blood Rev 28:31\u201340. https:\/\/doi.org\/10.1016\/j.blre.2014.01.001","journal-title":"Blood Rev"},{"key":"5683_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20:295\u2013308. https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"5683_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.13537","volume":"171","author":"D Pulte","year":"2015","unstructured":"Pulte D, Jansen L, Castro FA et al (2015) Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol 171:189\u2013196. https:\/\/doi.org\/10.1111\/bjh.13537","journal-title":"Br J Haematol"},{"key":"5683_CR45","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2165\/00003495-200767130-00005","volume":"67","author":"SR Shah","year":"2007","unstructured":"Shah SR, Tran TM (2007) Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs 67:1869\u20131881. https:\/\/doi.org\/10.2165\/00003495-200767130-00005","journal-title":"Drugs"},{"key":"5683_CR46","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s40265-017-0833-y","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma. Drugs 77:1897\u20131908. https:\/\/doi.org\/10.1007\/s40265-017-0833-y","journal-title":"Drugs"},{"key":"5683_CR47","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2010.030759","volume":"96","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, de Weers M, van Kessel B et al (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96:284\u2013290. https:\/\/doi.org\/10.3324\/haematol.2010.030759","journal-title":"Haematologica"},{"key":"5683_CR48","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E et al (2022) Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol 40:2901\u20132912. https:\/\/doi.org\/10.1200\/JCO.21.01935","journal-title":"J Clin Oncol"},{"key":"5683_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B et al (2024) Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol 42:26\u201337. https:\/\/doi.org\/10.1200\/JCO.23.01696","journal-title":"J Clin Oncol"},{"key":"5683_CR50","unstructured":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2312054. Accessed 1 Feb 2024"},{"key":"5683_CR51","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA et al (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114:1729\u20131735. https:\/\/doi.org\/10.1182\/blood-2009-04-205013","journal-title":"Blood"},{"key":"5683_CR52","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/s41409-022-01831-2","volume":"57","author":"B Sebastien","year":"2022","unstructured":"Sebastien B, Cheverton P, Magnin C et al (2022) Development and validation of a predictive model to guide the use of plerixafor in pediatric population. Bone Marrow Transplant 57:1827\u20131832. https:\/\/doi.org\/10.1038\/s41409-022-01831-2","journal-title":"Bone Marrow Transplant"},{"key":"5683_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D (2020) BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 13:125. https:\/\/doi.org\/10.1186\/s13045-020-00962-7","journal-title":"J Hematol Oncol"},{"key":"5683_CR54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"G Lancman","year":"2021","unstructured":"Lancman G, Sastow DL, Cho HJ et al (2021) Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discov 2:423\u2013433. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0028","journal-title":"Blood Cancer Discov"},{"key":"5683_CR55","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","volume":"14","author":"T Mark","year":"2008","unstructured":"Mark T, Stern J, Furst JR et al (2008) Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 14:795\u2013798. https:\/\/doi.org\/10.1016\/j.bbmt.2008.04.008","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:02:59Z","timestamp":1729933379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5683"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05683-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}